PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Recruiting Phase 1 Interventional Study
Graft Versus Host Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 70
Sex
Any
Trial phase
Phase 1
Study type
Interventional
Purpose
Prevention
Participants needed
18 (estimated)
Sponsor
Henry Ford Health System · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
So this a Phase I study with primary objective to determine the feasibility and safety of combining post-transplant cyclophosphamide and urinary-derived human chorionic gonadotropin and epidermal growth factor (uhCG/EGF) as graft versus host disease prophylaxis in stem cell transplant with MMUDs Secondary objectives are to determine the incidence acute and chronic GVHD, progression-free survival ,…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patients with hematologic malignancy who have the indication for Allogeneic SCT and have no MRD or MUD. 2. Age 18-70 years old 3. Performance score of at least 80% by Karnofsky 4. Adequate kidney and liver function as demonstrated by: 1. Creatinine clearance should be \>6…
Contacts

shatha farhan

3137133910

sfarhan1@hfhs.org

CONTACT